Filtered By:
Cancer: Lymphoma
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 33102 results found since Jan 2013.
Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors
CONCLUSIONS: Our results summarized the efficacy of these treatments and showed that only pembrolizumab can have a role as the first-line treatment of NSCLC. These findings are at variance with those previously reported using the hazard ratio as the outcome measure.PMID:33660798 | DOI:10.26355/eurrev_202102_25083
Source: European Review for Medical and Pharmacological Sciences - March 4, 2021 Category: Drugs & Pharmacology Authors: L Di Spazio L Cancanelli M Rivano M Chiumente D Mengato A Messori Source Type: research
Rationale behind using valproic acid for Non-Hodgkin lymphoma: a biomolecular perspective
CONCLUSIONS: Based on its biomolecular mechanism of action, VPA appears to be a promising initial treatment before initiating the standard treatment in patients with NHL to overcome resistance.PMID:34919251 | DOI:10.26355/eurrev_202112_27448
Source: European Review for Medical and Pharmacological Sciences - December 17, 2021 Category: Drugs & Pharmacology Authors: H Ridwansyah I Wijaya M H Bashari A H S Kartamihardja B S Hernowo Source Type: research
